The Morningstar US Basic Materials Index slightly outperformed the US Market Index during the fourth quarter of 2025. Yet we continue to see significant opportunities across the sector, with 55% of ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...
The number of Gen Z college freshmen who are entering universities without high school math skills is skyrocketing — as SAT scores are plummeting, a stunning new report has found. Even more shocking: ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Dr. Berg teaches philosophy at the University of California, Irvine. Last spring, it became clear to me that over half the students in my large general education lecture course had used artificial ...
In the era of vibe coding, when even professionals are pawning off their programming work on AI tools, Microsoft is throwing it all the way back to the language that launched a billion devices. On ...
This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...
The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. This was largely due to news from a ...